Moligo Technologies raises seed investment to bring advanced DNA synthesis technology to market
- Industrial scale production of ultra-pure DNA will begin for genome editing & synthetic biology
(STOCKHOLM, September 23rd 2020)—Moligo Technologies, a startup which produces long and ultra-pure DNA oligonucleotides at industrial scale, today announced that they successfully closed a seed funding round led by Colibri Ventures.
The seed funding will be used to establish Moligo Technologies as leader in the DNA synthesis industry and allow them to bring long, complex and ultra-pure DNA strands to the market at industrial scales.
Moligo Technologies founder and CEO Dr. Cosimo Ducani expressed his ambition for a fruitful partnership going forward, stating, “we are very thankful to Colibri Ventures for seeing the uniqueness and the potential of our enzymatic DNA synthesis technology, which will make the purest and longest DNA ever synthesized accessible at large scale, forever revolutionizing many industries, from therapeutics to agriculture.”
“Colibri Ventures invests in early life science innovations with the goal of commercializing groundbreaking discoveries by talented entrepreneurs. We are delighted to be part of the Moligo team”, says Dr. Fredrik Dahl, partner of Colibri Ventures who led the financing round. “The Moligo DNA synthesis technology will help accelerate and enable novel DNA-based research areas, diagnostics and drug development projects within precision medicine”.
The Moligo Technologies Team
Left to right: Dr. Lech Ignatowicz, Dr. Simon Fredriksson, Dr. Cosimo Ducani & Dr. Fredrik Dahl
Dr. Simon Fredriksson and Dr. Fredrik Dahl from Colibri Ventures have today, joined the board of Moligo Technologies where their mentorship and advice will help to shape the future of the company. They join existing board member Dr. Lech Ignatowicz who is a pre-seed investor in Moligo Technologies through Nordic Science Capital and welcomes the partnership with Colibri Ventures. “The team at Colibri Ventures has years of experience in the scientific and commercial side of molecular biology – from forming their own companies to running large organisations, investments and generating successful exits,” explained Ignatowicz. “This is textbook smart money and we are very glad that we can work together on this project”.
Moligo Technologies have also established R&D facilities at the Colibri Ventures life science incubator on the Karolinska Institute campus where work will continue to develop strategic applications for large scale production of long and extremely pure DNA strands.
ENDS
For more information, please contact Moligo Technologies CEO, Dr. Cosimo Ducani +46 76 555 07 67
About Moligo Technologies
The mission of Moligo Technologies is to enable the next generation of DNA based tools. From research to genome editing and diagnostics, Moligo Technologies produce long and pure, single stranded DNA that is not limited by complexity, multifunctionality or scale. The goal of Moligo Technologies is to push the limit of what is possible in genome editing by providing the best tools that improve precision and reduce unexpected off-target effects. They do this by producing DNA strands that are over 10 000 bases long and over 99.99999% pure. Moligo Technologies method also allows the production of DNA with any modifications or complexity which removes many of the limitations currently on researchers and pharmaceutical companies. They also aim to make sure that new technologies are not limited by scale. Unlike others, Moligo Technology’s method can be scaled to produce kilograms of DNA meaning that they will easily supply all the material for large experiments and clinical trials.